Evercore ISI Lowers Twist Bioscience (NASDAQ:TWST) Price Target to $42.00

Key Points

• Evercore ISI has lowered its price target for Twist Bioscience (TWST) from $46.00 to $42.00, maintaining an "outperform" rating, which suggests a potential upside of 33.59% from its current price.
• Other analysts, including Barclays and Weiss Ratings, have varied assessments on the stock, with Barclays reducing their target to $40.00 and Weiss giving a "sell (d-)" rating.
• Twist Bioscience reported a quarterly loss of ($0.47) earnings per share, surpassing analysts' expectations, and had a revenue of $96.06 million for the quarter, higher than the consensus estimate of $95.52 million.

Twist Bioscience (NASDAQ:TWST - Get Free Report) had its target price lowered by analysts at Evercore ISI from $46.00 to $42.00 in a research note issued on Tuesday,Benzinga reports. The brokerage presently has an "outperform" rating on the stock. Evercore ISI's target price would indicate a potential upside of 33.59% from the company's current price.

A number of other equities research analysts also recently issued reports on TWST. Weiss Ratings reiterated a "sell (d-)" rating on shares of Twist Bioscience in a research report on Saturday, September 27th. Barclays lowered their price target on Twist Bioscience from $45.00 to $40.00 and set an "overweight" rating on the stock in a research report on Thursday, October 2nd. Finally, Cowen restated a "buy" rating on shares of Twist Bioscience in a research report on Monday, August 4th. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Twist Bioscience presently has an average rating of "Moderate Buy" and a consensus price target of $48.50.

Twist Bioscience Price Performance

Shares of TWST stock traded down $0.41 on Tuesday, reaching $31.44. The company's stock had a trading volume of 1,836,502 shares, compared to its average volume of 1,261,218. The company has a quick ratio of 3.60, a current ratio of 3.90 and a debt-to-equity ratio of 0.03. Twist Bioscience has a 12-month low of $24.07 and a 12-month high of $55.33. The company has a market capitalization of $1.90 billion, a P/E ratio of -21.75 and a beta of 2.38. The stock's 50 day simple moving average is $27.83 and its 200-day simple moving average is $32.85.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.54) by $0.07. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%.The company had revenue of $96.06 million for the quarter, compared to the consensus estimate of $95.52 million. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, equities analysts predict that Twist Bioscience will post -2.12 earnings per share for the current fiscal year.

Insider Transactions at Twist Bioscience

In other news, CEO Emily M. Leproust sold 2,265 shares of the firm's stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $25.76, for a total transaction of $58,346.40. Following the transaction, the chief executive officer directly owned 634,740 shares of the company's stock, valued at approximately $16,350,902.40. This trade represents a 0.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Adam Laponis sold 2,449 shares of the firm's stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $38.15, for a total value of $93,429.35. Following the transaction, the chief financial officer directly owned 103,569 shares in the company, valued at $3,951,157.35. This trade represents a 2.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 8,436 shares of company stock worth $251,632 over the last ninety days. Insiders own 3.01% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. ARK Investment Management LLC grew its stake in shares of Twist Bioscience by 2.5% in the second quarter. ARK Investment Management LLC now owns 6,400,441 shares of the company's stock worth $235,472,000 after purchasing an additional 158,846 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Twist Bioscience by 1.0% in the first quarter. Vanguard Group Inc. now owns 5,867,459 shares of the company's stock worth $230,356,000 after purchasing an additional 60,276 shares during the last quarter. William Blair Investment Management LLC grew its stake in shares of Twist Bioscience by 2.6% in the second quarter. William Blair Investment Management LLC now owns 3,906,604 shares of the company's stock worth $143,724,000 after purchasing an additional 99,737 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Twist Bioscience by 186.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,442,262 shares of the company's stock worth $95,883,000 after purchasing an additional 1,588,587 shares during the last quarter. Finally, EdgePoint Investment Group Inc. grew its stake in shares of Twist Bioscience by 114.3% in the second quarter. EdgePoint Investment Group Inc. now owns 2,385,942 shares of the company's stock worth $87,779,000 after purchasing an additional 1,272,732 shares during the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.